A two-year study on the new diabetes pill being developed by Bristol-Meyers and AstraZeneca was found to increase the risk of breast and bladder cancers though the drug was effective.
According to AstraZeneca's Elisabeth Bjork, around 1.4 percent of those who were taking the drug, known as dapagliflozin, developed some form of cancer compared to 1.3 percent of those who did not take the drug during the study.
AdvertisementAnalysts have pegged the annual sales of dapagliflozin to be over $631 million by 2015 but rejection of the drug by the Food and Drug Administration could cut the earnings of the companies by 3 to 6 percent.
P “Lean” Gene Supposedly Increases Risk of Type 2 Diabetes Genentech to Lodge Appeal for Saving Avastin M
You May Also Like